Provider review
Science & Co review: care promises and inconsistent outcome figures
Science & Co offers online assessment, provider review and ongoing support. Its current homepage outcome card pairs a 222-to-189-pound example with figures of 34 pounds and 14.4%; those numbers do not reconcile. Before choosing a plan, confirm the prescribed product, full payment commitment and dispensing pharmacy.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit Science & CoOf Science & Co’s 2 dated product claims documented below, 2 are consistent with the cited evidence. Among the dated prices documented below, the lowest listed upfront charge is $79 for 30 days (Compounded semaglutide injection, on the twelve-month plan). A matching claim does not mean the compounded product was tested or FDA-approved.
Current homepage outcome figures do not reconcile. Verify the actual medication, payment commitment and pharmacy instead of choosing from illustrative results.
Worth trusting if
- You want online provider review and follow-up
- You are willing to confirm the exact product and full financial commitment before payment
Be skeptical if
- You need outcome figures with clear methods and consistent arithmetic
- You need a current personalized quote before comparing total costs
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Science & Co
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — September price capture: $79 a month on the twelve-month plan, against a $149 reference rate.
- Compounded tirzepatide injection — September price capture: $125 a month on the twelve-month plan, against a $199 reference rate.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 2 products reviewed here. The evidence concerns the molecule, not Science & Co's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Science & Co’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“222 lbs → 189 lbs. 15% lost on average. Steady, provider guided progress you can track month to month. Same Price, Any Dose.”
Read on the Science & Co site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults with a body-mass index of 30 or above, or 27 or above with a weight-related condition. Reported a mean weight reduction of about 15% on semaglutide 2.4 mg against about 2% on placebo.
Historical September product-page capture: 222 to 189 pounds equals 33 pounds, or approximately 14.9%. Similarity to STEP 1 does not establish that the seller derived the example from that study. The October homepage now includes inconsistent 34-pound and 14.4% labels, discussed below.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“Compounded Tirzepatide (Injection), prescribed by a licensed provider and built around your history, your goals and how your body actually responds. Same Price, Any Dose.”
Read on the Science & Co site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly. Reported a mean reduction of roughly 20% at the top dose.
The tirzepatide page makes no outcome claim at all — no percentage, no worked example, no timeline. It describes what the drug is and how the plan works, and leaves the result unstated. That is a defensible position rather than an evasive one, though it does mean the page selling the more effective of the two molecules says less about what it does than the page selling the other. The flat-price promise is repeated here and is a commercial claim rather than a clinical one.2
Dispensing chain
Who actually fills your prescription
Read the full account
Science & Co names no pharmacy — but it does something rarer than naming one, which is to say what it is not. Its terms state twice that the company is not a 503A or 503B compounding facility, meaning it neither makes drugs to order nor manufactures them in bulk itself, and adds that it may offer compounded medications from registered U.S. facilities. Usually, neither of those regulatory terms appears anywhere on a seller's site at all. That is a clearer position than most of this market takes, and it still leaves the actual facility unnamed, along with every clinician.
Read on the Science & Co site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
The September source review did not verify a public batch certificate or a detailed testing regime. This is a limit of the published evidence checked, not proof that a pharmacy performs no testing. The current outcome-card discrepancy is discussed separately in the October review.
Read on the Science & Co site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Science & Co publishes no list of states and claims no nationwide coverage, on its product pages, its FAQ or its terms. Its terms govern use of the website rather than describing a service area.
Read the full licensing claim
The operator is named and its corporate form and state are given: Science and Co, Inc., a Delaware corporation. A telephone number is published. No street address appears, and no clinician, medical director or advisory panel is named.
Read on the Science & Co site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- The platform distinguishes itself from a compounding pharmacy.
- Public copy describes clinical review and ongoing support.
- The site distinguishes compounded products from approved brands.
- Current outcome-card figures do not reconcile.
- Historical prepaid pricing does not establish a current single-month offer.
- A dispensing pharmacy and cancellation cutoff need to be confirmed for the actual prescription.
Verdict
The bottom line
The service may be convenient, but an outcome card is not a forecast or proof of trial provenance. Request the exact plan total, renewal terms, laboratory charges and dispensing pharmacy before committing; older twelve-month price captures are not fresh quotes.
Opens Science & Co's website. A link is not a recommendation to take anything.
What the current outcome card says
On October 13, 2026, the homepage showed a change from 222 to 189 pounds, alongside a 34-pound loss and a 14.4% average. Subtraction gives 33 pounds; dividing by 222 gives about 14.9%. We cannot resolve those different figures from the card itself. 3
Our September review praised an older 15% label for resembling STEP 1. That resemblance never established where the seller obtained its figure, and the current card no longer matches that description. STEP 1 measured a group average over 68 weeks, not the expected outcome of a named customer's plan. 1 A numerical similarity is not a citation.
Full analysis — 3 more sectionsWhat care is advertised · Match the evidence to the prescription · Clarify how to stop
What care is advertised
The current homepage describes an online questionnaire, licensed-provider review, monthly follow-up and laboratory testing when needed. It advertises no membership fee and ongoing support. Those are public service descriptions, not response times or experiences we have tested. 3
Before paying, ask whether your quoted amount includes the medication, clinician visits, laboratory work and shipping. A service can have no membership fee yet still require a substantial prepaid medication purchase. The twelve-month prices captured elsewhere in this review retain their September verification dates; they should not be treated as a new checkout quote.
Match the evidence to the prescription
The catalog includes compounded products, branded weight-loss medicines, NAD+ and sermorelin. That range does not make the evidence interchangeable. Ask which exact product you would receive, why it fits your clinical circumstances and what outcome the clinician expects to monitor. 3
Science & Co states that it is not itself a 503A or 503B compounding facility. The practical follow-up is to obtain the name and license details of the actual dispensing pharmacy. A platform's identity and a pharmacy's identity answer different questions.
Clarify how to stop
The published shipping and returns policy requires cancellation at least 72 hours before the next processing date. It distinguishes stopping future subscription orders from refunding medication already dispensed, and offers support for lost or damaged packages. Confirm the processing date in your account rather than counting back from the delivery date. 3 We have not tested intake, paid for treatment or measured support response times; the assessment here concerns published information.
Questions
Frequently asked questions
Does the current weight-loss example add up?
No single calculation reconciles the displayed figures: 222 minus 189 is 33 pounds, or about 14.9%, while the current card also says 34 pounds and 14.4%. Ask for the underlying population, time period and calculation.
Are the listed twelve-month prices current quotes?
They are historical captures with September verification dates. Confirm the full upfront payment, renewal amount and inclusions before relying on them.
Does no membership fee mean no extra costs?
Not necessarily. Confirm medication, laboratory, consultation and shipping costs for your exact plan, along with any prepaid term.
Glossary
Key terms
Show definitions
- 503A and 503B
- The two categories of compounding pharmacy under US law. A 503A makes a drug to order for one named patient; a 503B is an outsourcing facility that can make batches. Neither produces an FDA-approved finished product.
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022.
Compare
Others selling what Science & Co sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Science & Co is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Science & Co's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 4 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults over 68 weeks, mean weight reduction of about 15%. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults over 72 weeks at 5, 10 and 15 mg once weekly. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
- Publisher (2026). Science & Co public service and outcomes page, checked October 13. Public primary source. the Science & Co site
- Publisher (2026). Science & Co shipping and returns policy, checked October 13. Public primary source. the Science & Co site
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.